EP3630768 - (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.10.2021 Database last updated on 31.08.2024 | |
Former | Grant of patent is intended Status updated on 14.01.2021 | ||
Former | Request for examination was made Status updated on 06.03.2020 | ||
Former | The international publication has been made Status updated on 08.12.2018 | ||
Former | unknown Status updated on 19.06.2018 | Most recent event Tooltip | 18.10.2021 | Application deemed to be withdrawn | published on 17.11.2021 [2021/46] | Applicant(s) | For all designated states ESTEVE PHARMACEUTICALS, S.A. Passeig de la Zona Franca, 109, 4ª Planta 08038 Barcelona / ES | [2020/15] | Inventor(s) | 01 /
YENES-MINGUEZ, Susana Passeig Terraplè 71 3°, 1a 08750 Molins de Rei Barcelona / ES | 02 /
FERNANDEZ-DONIS, Ariadna c/ Enric Granados 107 08025 Barcelona / ES | 03 /
ALMANSA-ROSALES, Carmen c/ Teodora Lamadrid 41 08022 Barcelona / ES | [2020/15] | Application number, filing date | 18729367.5 | 29.05.2018 | [2020/15] | WO2018EP64037 | Priority number, date | EP20170382310 | 30.05.2017 Original published format: EP 17382310 | [2020/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018219927 | Date: | 06.12.2018 | Language: | EN | [2018/49] | Type: | A1 Application with search report | No.: | EP3630768 | Date: | 08.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.12.2018 takes the place of the publication of the European patent application. | [2020/15] | Search report(s) | International search report - published on: | EP | 06.12.2018 | Classification | IPC: | C07D487/04, A61K31/4985, A61P25/04 | [2020/15] | CPC: |
C07D487/04 (EP,US);
A61P25/04 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/15] | Title | German: | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINDERIVATE MIT MULTIMODALER AKTIVITÄT GEGEN SCHMERZEN | [2021/01] | English: | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | [2020/15] | French: | DERIVES DE (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE AVEC ACTIVITE MULTIMODALE CONTRE DOULEUR | [2021/01] |
Former [2020/15] | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZIN-DERIVATE MIT MULTIMODALER AKTIVITÄT GEGEN SCHMERZEN | ||
Former [2020/15] | DÉRIVÉS D'(HÉTÉRO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR | Entry into regional phase | 02.01.2020 | National basic fee paid | 02.01.2020 | Designation fee(s) paid | 02.01.2020 | Examination fee paid | Examination procedure | 02.01.2020 | Examination requested [2020/15] | 02.01.2020 | Date on which the examining division has become responsible | 13.07.2020 | Amendment by applicant (claims and/or description) | 15.01.2021 | Communication of intention to grant the patent | 26.05.2021 | Application deemed to be withdrawn, date of legal effect [2021/46] | 01.07.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2021/46] | Fees paid | Renewal fee | 02.06.2020 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.05.2021 | 04   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I] - MYATT JAMES W ET AL, "Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20100531), vol. 20, no. 15, doi:10.1016/J.BMCL.2010.05.026, ISSN 0960-894X, pages 4683 - 4688, XP029121111 [I] 1-13 * Compounds in Table 1; fitst column on page 4684 last two paragraphs and second comumn on page 4684 fist paragraph; * DOI: http://dx.doi.org/10.1016/j.bmcl.2010.05.026 | by applicant | - TURK, D.C.; WILSON, H.D.; CAHANA, A., Lancet, (20110000), vol. 377, pages 2226 - 2235 | - GOLDBERG, D.S.; MCGEE, S.J., BMC Public Health, (20110000), vol. 11, page 770 | - ZAMPONI et al., Pharmacol. Rev., (20150000), vol. 67, pages 821 - 70 | - PERRET; LUO, Neurotherapeutics, (20090000), vol. 6, pages 679 - 92 | - NEUMAIER et al., Prog. Neurobiol., (20150000), vol. 129, pages 1 - 36 | - VINK; ALEWOOD, Br J Pharmacol., (20120000), vol. 167, pages 970 - 89 | - DAVIES et al., Trends Pharmacol Sci., (20070000), vol. 28, pages 220 - 8 | - DOLPHIN AC, Nat Rev Neurosci., (20120000), vol. 13, pages 542 - 55 | - Biochim Biophys Acta, (20130000), vol. 1828, pages 1541 - 9 | - MASON,S.T., Prog. Neurobiol., (19810000), vol. 16, pages 263 - 303 | - KASPER et al., Expert Opin. Pharmacother., (20000000), vol. 1, pages 771 - 782 | - OSSIPOV et al., J. Clin. Invest., (20100000), vol. 120, pages 3779 - 3787 | - WANG et al., J. Pain, (20130000), vol. 14, pages 845 - 853 | - CHABOT-DORE et al., Neuropharmacology, (20150000), vol. 99, pages 285 - 300 | - FAIRBANKS et al., Pharmacol. Ther., (20090000), vol. 123, pages 224 - 238 | - MOCHIZUCKI,D., Psychopharmacol, (20040000), pages S15 - S19 | - HARTRICK,C.T., Expert Opin. Investig. Drugs, (20120000), vol. 21, pages 1827 - 1834 | - LEHAR et al., Nat. Biotechnol., (20090000), vol. 27, pages 659 - 666 | - GILRON et al., Lancet Neurol., (20131100), vol. 12, no. 11, pages 1084 - 95 | - SCHRODER et al., J Pharmacol. Exp. Ther., (20110000), vol. 337, pages 312 - 20 | - J Pharmacol. Exp. Ther., (20120000), vol. 342, page 232 | - ZHANG et al., Cell Death Dis., (20140000), vol. 5, page e1138 | - HOPKINS, Nat. Chem. Biol., (20080000), vol. 4, pages 682 - 90 | - NICOLSON et al., Harv. Rev. Psychiatry, (20090000), vol. 17, pages 407 - 420 | - HAYASHIDA,K., Eur. J. Pharmacol., (20080000), vol. 598, pages 21 - 26 | - MIRANDA,H.F. et al., J. Orofac. Pain, (20130000), vol. 27, pages 361 - 366 | - Pharmacology, (20150000), vol. 95, pages 59 - 64 | - FRAMPTON,J.E., CNS Drugs, (20140000), vol. 28, pages 835 - 854 | - HAJOS,M. et al., CNS Drug Rev., (20040000), vol. 10, pages 23 - 44 | - MAO, J.; GOLD, M.S.; BACKONJA, M., J. Pain, (20110000), vol. 12, pages 157 - 166 |